Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-135 in advanced solid tumors
NCT03464032Phase 1Unknown
- Sponsor
- BIOCAD
- Start
- Oct 2017
- Primary completion
- May 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of manelimab in melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and 1 more, sponsored by BIOCAD. Primary endpoint: Disease Control Rate at 85 days. Status: unknown.
02
Drugs
manelimab
03
Conditions
melanomanon-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)bladder cancer
Beyond the preview
Go deeper on NCT03464032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03464032.